Venetoclax and Azacitidine Combination is an Effective Salvage Regimen for Fit Patients with IDH-2-mutated Acute Myeloid Leukemia Refractory to Conventional Induction Chemotherapy
Acute myeloid leukemia (AML) constitutes a heterogeneous group of clonal myeloid neoplasms that is associated with a large number of recurrent genetic abnormalities. Mutations in IDH2 gene can be found in nearly 10% of newly diagnosed AML patients. The impact of IDH2 mutations on prognosis in the ab...
Saved in:
Main Author: | Musa Fares Alzahrani |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2024-12-01
|
Series: | Journal of Applied Hematology |
Subjects: | |
Online Access: | https://journals.lww.com/10.4103/joah.joah_97_24 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress
by: Jenna L. Carter, et al.
Published: (2025-01-01) -
Left Kidney Undifferentiated Spindle Cell Sarcoma with Myeloid Cell Leukemia-1 Amplification: Therapeutic Response to Bortezomib, Venetoclax, and Dexamethasone Therapy
by: Cheng-Yu Tang, et al.
Published: (2023-10-01) -
Hemophagocytic lymphohistiocytosis secondary to refractory acute myeloid leukemia resolved after second line treatment with azacitidine plus venetoclax
by: Claudio Fozza
Published: (2024-01-01) -
Venetoclax in combination with chidamide and azacitidine for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia with the MLL-AF4 gene: a case report and literature review
by: Xuelian Jin, et al.
Published: (2025-01-01) -
miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting
by: Yilan Xu, et al.
Published: (2025-02-01)